Company Quick10K Filing
Idexx Laboratories
Closing Price ($) Shares Out (MM) Market Cap ($MM)
$0.00 88 $23,646
10-Q 2019-10-31 Quarter: 2019-09-30
10-Q 2019-08-01 Quarter: 2019-06-30
10-Q 2019-05-01 Quarter: 2019-03-31
10-K 2019-02-15 Annual: 2018-12-31
10-Q 2018-11-01 Quarter: 2018-09-30
10-Q 2018-08-01 Quarter: 2018-06-30
10-Q 2018-05-04 Quarter: 2018-03-31
10-K 2018-02-16 Annual: 2017-12-31
10-Q 2017-10-31 Quarter: 2017-09-30
10-Q 2017-08-01 Quarter: 2017-06-30
10-Q 2017-04-28 Quarter: 2017-03-31
10-K 2017-02-17 Annual: 2016-12-31
10-Q 2016-11-01 Quarter: 2016-09-30
10-Q 2016-08-02 Quarter: 2016-06-30
10-Q 2016-04-29 Quarter: 2016-03-31
10-K 2016-02-17 Annual: 2015-12-31
10-Q 2015-10-28 Quarter: 2015-09-30
10-Q 2015-07-30 Quarter: 2015-06-30
10-Q 2015-04-28 Quarter: 2015-03-31
10-K 2015-02-17 Annual: 2014-12-31
10-Q 2014-10-24 Quarter: 2014-09-30
10-Q 2014-07-25 Quarter: 2014-06-30
10-Q 2014-04-25 Quarter: 2014-03-31
10-K 2014-02-18 Annual: 2013-12-31
10-Q 2013-10-22 Quarter: 2013-09-30
10-Q 2013-07-23 Quarter: 2013-06-30
10-Q 2013-04-23 Quarter: 2013-03-31
10-K 2013-02-19 Annual: 2012-12-31
10-Q 2012-10-19 Quarter: 2012-09-30
10-Q 2012-07-20 Quarter: 2012-06-30
10-Q 2012-04-20 Quarter: 2012-03-31
10-K 2012-02-17 Annual: 2011-12-31
10-Q 2011-10-21 Quarter: 2011-09-30
10-Q 2011-07-22 Quarter: 2011-06-30
10-Q 2011-04-21 Quarter: 2011-03-31
10-K 2011-02-22 Annual: 2010-12-31
10-Q 2010-10-22 Quarter: 2010-09-30
10-Q 2010-07-23 Quarter: 2010-06-30
10-Q 2010-04-23 Quarter: 2010-03-31
10-K 2010-02-19 Annual: 2009-12-31
8-K 2019-10-31 Earnings, Exhibits
8-K 2019-10-23 Officers, Regulation FD, Exhibits
8-K 2019-08-05 Officers
8-K 2019-08-01 Earnings, Exhibits
8-K 2019-07-24 Regulation FD, Exhibits
8-K 2019-07-16 Officers, Exhibits
8-K 2019-06-28 Officers, Exhibits
8-K 2019-05-08 Shareholder Vote
8-K 2019-05-01 Earnings, Exhibits
8-K 2019-03-14 Enter Agreement, Off-BS Arrangement, Exhibits
8-K 2019-02-01 Earnings, Exhibits
8-K 2018-11-01 Earnings, Exhibits
8-K 2018-08-01 Earnings, Exhibits
8-K 2018-06-13 Officers
8-K 2018-05-09 Officers, Shareholder Vote
8-K 2018-05-04 Earnings, Exhibits
8-K 2018-02-14 Officers
8-K 2018-02-01 Earnings, Exhibits
8-K 2018-01-05 Earnings, Regulation FD, Exhibits

Idexx Laboratories Financials

IDXX Metrics, Comps, Filings

Annual | Quarterly

Business

IDEXX was incorporated in Delaware in 1983. We develop, manufacture, and distribute products and provide services primarily for the companion animal veterinary, livestock and poultry, dairy and water testing markets. We also sell a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market. Our primary products and services are:

-Point-of-care veterinary diagnostic products, comprised of instruments, consumables, and rapid assay test kits;

-Veterinary reference laboratory diagnostic and consulting services;


Valuation ($BB)

Market Cap, Enterprise Value

Balance Sheet ($BB)

Assets, Stockholders' Equity

Income Statement ($BB Annual)

Revenue, Gross Profit, Net Income

Cash Flow ($BB Annual)

Operating, Investing, Financing

Comps ($MM TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Idexx Laboratories (IDXX) 23,646 57% 37.7 24% 1,724 1,553 2,291 1,295 417 624 23,536
Neogen (NEOG) 4,151 46% 44.9 8% 721 61 416 193 60 91 4,095
Quidel (QDEL) 2,482 60% 22.8 8% 846 336 506 302 69 108 2,453
Immunomedics (IMMU) 2,456 0% -6.7 -72% 478 363 0 0 -344 -301 2,026
Myriad Genetics (MYGN) 2,016 0% 21.1 0% 1,563 474 851 0 5 102 2,157
Lantheus Holdings (LNTH) 1,112 51% 25.8 3% 390 298 347 177 13 49 1,255
Intellia Therapeutics (NTLA) 727 100% -8.1 -25% 352 76 37 37 -89 -84 678
Quotient (QTNT) 626 40% 1,004.8 -54% 193 215 29 12 -104 -89 -89,908
Meridian Bioscience (VIVO) 490 60% 11.8 8% 322 134 203 121 26 43 511
Oxford Immunotec Global (OXFD) 370 72% 1.9 56% 242 24 66 48 137 96 183
Trinity Biotech (TRIB) 235 0% 152 108 0 0 0 0 228
Oncocyte (OCX) 130 -5.8 -44% 38 4 0 0 -17 -16 94
Volitionrx (VNRX) 125 -6.7 -75% 23 6 0 0 -17 -16 109
Nymox Pharmaceutical (NYMX) 92 0% 8 1 0 0 0 0 92
Vermillion (VRML) 82 17% -5.2 -74% 18 5 4 1 -14 -13 67
Riot Blockchain (RIOT) 69 12% -1.8 -105% 31 5 8 1 -32 -29 53
Immucell (ICCC) 48 47% 141.5 -5% 39 10 12 6 -2 0 46
Celldex Therapeutics (CLDX) 38 0% 6.4 0% 142 33 5 0 0 3 18
Achieve Life Sciences (ACHV) 20 -0.6 -111% 15 3 0 0 -16 -16 9
Navidea Biopharmaceuticals (NAVB) 12 100% -0.6 -149% 8 5 1 1 -12 -12 7

Balance Sheet ($MM)2010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-31
Cash157184224279323129155188124
Accounts Receivable120141138158152188204235249
Inventory128133141133160189158164173
PP&E202217245550304333357379437
Assets8971,0311,1041,2311,3841,4751,5311,7131,537
Accounts Payable233735304553603741
Long-Term Debt33151367594594632607
Liabilities3234914677121,2671,5591,6391,7671,547
Stockholders' Equity574540636518118-84-108-54-10
Income Statement ($MM)2010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-31
Revenue3854364765238996271,7757932,213
Cost of Revenue239262288302335712800425972
Gross Profit5796476997568168909751,0971,242
R&D6976828898100101109118
SG&A306334355401458482524575632
Tax6173827560557511881
Net Income141162178188182192222263377
Cash Flow ($MM)2010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-31
Cash Operating179221230246236216335373400
Cash Investing-43-97-66-86-80-308-91-139139
Cash Financing-87-98-125-102-103-96-218-208-598